A KalVista Pharmaceuticals eye drug at the center of a research collaboration with Merck has failed a mid-stage clinical trial.
Vice president, chief strategy and operating officer of the Texas Medical Center
Managing Director, D.E. Shaw and Co., L.P.
CEO and Fund Manager, Renaissance Venture Capital Fund
Vice President for Research at UT Health Science Center at San Antonio
[Corrected 12:27 p.m. See below.] The FDA has rejected an experimental regenerative therapy that Enzyvant developed to restore immune system function in babies born with a rare disorder. The agency cited manufacturing issues, according to the company.
Enzyvant received... Read more »
[Updated 12/4/19, 4:01 p.m. ET. See below.] Veracyte, a company whose tests help physicians make treatment decisions, is adding technology from NanoString to the fold to expand its diagnostic capabilities.
Bristol-Myers Squibb this week completed its acquisition of Celgene, a $74 billion deal that creates a pharmaceutical juggernaut. And all it took was the largest asset sale ever required by federal antitrust regulators.
As the Federal Trade Commission reviewed Bristol’s (NYSE:... Read more »
Drug pricing debates and uncertainty associated with Brexit are the issues most likely to keep biopharmaceutical executives awake at night. Nevertheless, senior figures remain optimistic about the industry’s prospects in 2020. These are among the major findings of a survey of... Read more »
The list of activities our smartphones can control grows daily. Transfer money? It’s simple. Order groceries? That, too. Turn off the bedroom lights? Check.
How about contraception?
Advancing new forms of birth control is a central focus at Daré Bioscience (NASDAQ:... Read more »
AstraZeneca says it will establish centers for drug research and artificial intelligence development in China. The pharmaceutical giant has also set up a $1 billion fund to foster biotech innovation in that country.
The doors have opened at a GE Healthcare-supported open-access lab for startups at AstraZeneca’s former global center for oncology research and development at Alderley Park, the largest bioscience research campus in the UK.
Eli Lilly won FDA approval for a migraine drug on Friday, giving the pharmaceutical giant a second medication that addresses the condition that causes millions of people to experience severe headaches and other debilitating symptoms.
The FDA approved the drug, lasmiditan... Read more »
Five years ago, the big tech incubator Y Combinator started to welcome life sciences companies into its sizable startup classes, which had previously nurtured entrepreneurs in information technology almost exclusively.
That opening to biotech startups in 2014 was controversial at the... Read more »
This summer Nestlé Health Science sold Prometheus Laboratories, a gastrointestinal disease diagnostics unit it had acquired eight years prior, to a low-profile San Diego biotech called Precision IBD.
About a month ago, Precision—a drug and diagnostic developer that’s focused, as... Read more »
President of the Council for Economic Development (CED)
Professor at the University of North Carolina at Chapel Hill
Chief Strategy and Innovation Officer, Blue Cross and Blue Shield of North Carolina
Managing Partner at Pappas Ventures
President, CEO, and Chairman of the Board of SciQuest
CEO of G1 Therapeutics
CEO and co-founder of BoostSuite
Vice President, Carolinas HealthCare System
Retired CEO of ShopperTrak RCT Corporation
CEO of the Marine Bio-Technologies Center of Innovation
Founder and CEO of Brooks Bell Inc.